To find a reference on this page either scroll or hold down the "Ctrl" key and press "f".
|
haematology
|
| abnormal laboratory results in children 27(3) 64-6 |
| diagnostic immunology - abnormal laboratory results 30(5) 128-9 |
|
haematopoietic stem cell transplantation
|
| adult leukaemia 29(3) 76-9 |
|
haemodialysis
|
| iron sucrose - iron deficiency anaemia - Venofer (New drug) 28(2) 49-51 |
| letter 28(4) 84-7 |
|
haemoglobin
|
| oximetry 26(6) 132-5 |
| nail polish removal (letter) 27(2) 28-33 |
|
haemoglobinopathies
|
| thalassaemia screening 24(5) 120-3 |
| letter 25(2) 27-8 |
|
haemophilia
|
| factor VIII inhibitor bypassing fraction - FEIBA-NF (New drug) 30(2) 50-55 |
| recombinant factor IX - haemophilia - Benefix (New drug) 24(3) 71-5 |
| recombinant factor VIII - moroctocog - Refacto (New drug) 25(4) 94-9 |
|
haemophilia A
|
| recombinant factor VIIa - NovoSeven (New drug) 22(4) 95-8 |
| recombinant factor VIII - Recombinate (New drug) 19(1) 24-7 |
|
Haemophilus influenzae type b
|
| conjugate vaccine - childhood immunisation 17(4) 91-4 |
| diphtheria, tetanus, pertussis, hepatitis B, polio and Haemophilus influenzae type b - Infanrix hexa (New combination) 27(6) 159-65 |
| hepatitis B - Comvax (New combination) 23(3) 64-7 |
| PedvaxHIB b (New formulation) 23(3) 64-7 |
|
haemorrhage
|
| warfarin and occult bleeding 24(4) 89 |
|
haemorrhagic disease of the newborn
|
| phytomenadione - Konakion (New formulation) 23(2) 45-6 |
|
haemostasis
|
| in surgery 23(1) 13-6 |
| letter 23(4) 72 |
| in surgery - fibrin sealant - Tisseel Duo 500 (New drug) 26(2) 46-7 |
| correction 26(4) 95 |
| letter 26(4) 75-7 |
|
haemostasis disorders
|
| dental implications 18(2) 48 |
| laboratory results 18(2) 38-41 |
|
hair growth reduction
|
| eflornithine hydrochloride - Vaniqa - facial hair (New drug) 29(3) 84-7 |
|
Havrix
|
| see hepatitis A vaccine 19(2) 38-40 |
|
hay fever - see rhinitis, allergic
|
|
HB-VAX-II
|
| see hepatitis B vaccine 24(4) 100-2 |
|
HDL cholesterol - see cholesterol
|
|
head lice
|
| management 23(3) 62-3 |
| letters 24(1) 3; 23(5) 93-6 |
|
headache (see also migraine)
|
| and analgesic overuse 28(6) 143-5 |
| letter 29(3) 59-62 |
| non-organic pain 22(5) 122-5 |
|
Health Insurance Commission
|
| prescriber feedback (editorials) 21(1) 2-3 |
|
HealthROM
|
| CD-ROM reference publication 17(3) 61 |
|
Healthy Skepticism
|
| AdWatch website review 27(3) 63 |
|
hearing disorders
|
| newborn hearing screening 26(4) 82-4 |
| patient support organisations 26(4) 87 |
|
heart arrest
|
| management 20(2) 41-5 |
| letters 21(3) 60-3; 20(4) 83-6 |
|
heart disease
|
| positron emission tomography 18(1) 13-5 |
|
heart failure, congestive
|
| beta blockers 23(6) 120-3 |
| bisoprolol fumarate - Bicor (New drug) 25(4) 94-9 |
| B-type natriuretic peptide - abnormal laboratory results 26(3) 64-5 |
| cardiovascular medicine in the 21st century (editorial) 23(1) 2 |
| carvedilol - Kredex, Dilatrend (New drug) 21(3) 80-3 |
| digoxin 22(6) 136-7 |
| dental implications 22(6) 144 |
| digoxin - letter 23(3) 55-6 |
| digoxin in doctor's bag supplies (PBAC question) 20(4) 86-7 |
| dopamine pharmacology 17(2) 42-3 |
| drug therapy 23(6) 118-20 |
| management of post myocardial infarct patients 19(1) 8-10 |
| palliative care (editorial) 26(5) 98-9 |
|
heart transplantation
|
| everolimus - Certican (New drug) 28(3) 75-9 |
|
heart valve diseases
|
| cabergoline-induced valvulopathy (medicinal mishap) 31(1) 21 |
|
heart valve prosthesis
|
| perioperative anticoagulation in patients with mechanical valves 23(1) 13-6 |
|
Helicobacter pylori
|
| abnormal laboratory results 20(4) 96-8 |
| letter 21(2) 31-4 |
| management of acid peptic disease 18(4) 97-9 |
| proton pump inhibitors - long-term management 31(1) 5-7 |
|
heparin
|
| in early management of myocardial infarction 19(2) 52-4 |
| perioperative anticoagulant management 23(1) 13-6 |
| in prevention of deep vein thrombosis 21(2) 37-9 |
| in treatment of deep vein thrombosis 21(3) 64-6 |
|
heparin, low molecular weight
|
| clinical pharmacology 19(4) 104-8 |
| correction 20(1) 20-1 |
| in coronary disease 24(3) 56-8 |
| fondaparinux - thromboembolism prophylaxis - Arixtra (New drug) 25(4) 94-9 |
| nadroparin calcium - Fraxiparine (New drug) 19(2) 38-40 |
| perioperative anticoagulant management 23(1) 13-6 |
| in prevention of deep vein thrombosis 21(2) 37-9 |
| PBAC question 21(4) 97 |
| tinzaparin - Logiparin (New drug) 17(1) 6-8 |
| in treatment of deep vein thrombosis 21(3) 64-6 |
|
heparin-associated thrombocytopenia
|
| lepirudin - Refludan (New drug) 23(4) 84-7 |
|
hepatitis A
|
| childhood immunisation 17(4) 91-4 |
| inactivated vaccine - Avaxim (New brand) 23(5) 110-1 |
| vaccine - Havrix 1440 (New strength) 19(2) 38-40 |
|
hepatitis B
|
| abnormal laboratory results and vaccination 21(3) 72-5 |
| dental implications 21(3) 79 |
| adefovir dipivoxil - Hepsera - (New drug) 27(6) 159-65 |
| childhood immunisations 17(4) 91-4 |
| entecavir - Baraclude (New drug) 29(5) 138-43 |
| hepatitis |
| needle-stick injuries 24(4) 98-100 |
| telbivudine - Sebivo (New drug) 30(6) 163-7 |
| vaccine - diphtheria, tetanus, pertussis, hepatitis B, polio - Infanrix penta (New combination) 27(6) 159-65 |
| vaccine - diphtheria, tetanus, pertussis, hepatitis B, polio, Haemophilus influenzae type b - Infanrix hexa 27(6) 159-65 |
|
hepatitis B vaccine
|
| diphtheria, tetanus, pertussis, hepatitis B, polio and Haemophilus influenzae type b - Infanrix penta and Infanrix hexa (New combinations) 27(6) 159-65 |
| HB-VAX-II (New formulation) 24(4) 100-2 |
|
hepatitis C
|
| abnormal laboratory results 22(1) 16-8 |
| dental notes 29(2) 52 |
| letter 30(3) 59-63 |
| management 29(2) 36-9 |
| needle-stick injuries 24(4) 98-100 |
| patient support organisation 29(2) 39 |
| peginterferon alfa 2b - Peg-Intron (New drug) 25(5) 120-3 |
| peginterferon alfa-2a/ribavirin combination - Pegasys (New drug) 26(6) 146-51 |
|
hepatitis, cholestatic
|
| flucloxacillin adverse reaction (editorial) 18(3) 54-6 |
| letter 19(1) 3-6 |
| vs dicloxacillin 21(1) 25-7 |
|
hepatotoxicity of ranitidine, diclofenac and phenytoin
|
| letter 19(4) 92-3 |
|
Hepsera
|
| see adefovir dipivoxil 27(6) 159-65 |
|
herbal preparations (see also complementary medicines)
|
| agnus castus and premenstrual syndrome 24(5) 123 |
| celery seed tablets and thyroxine 24(1) 6-7 |
| Chinese medicines - quality and safety 26(6) 128-30 |
| letter 27(2) 28-33 |
| guarana preparations and caffeine (letter) 21(1) 5-8 |
| iodine in herbal cough mixture (letter) 24(3) 51-5 |
| Oralmat Drops for oral pain relief (letter) 19(2) 36-8 |
| regulation 21(4) 107-8 |
| saw palmetto - benign prostatic hypertrophy 23(4) 79 |
| St John's wort as antidepressant 22(5) 112-3 |
|
Herceptin
|
| see trastuzumab 24(5) 129-31 |
|
heroin dependence
|
| buprenorphine - Subutex (New drug) 24(3) 71-5 |
| correction 24(5) 129-31 |
| drug treatment for opioid dependence 24(1) 4-6 |
| letter 24(3) 51-5 |
| naltrexone - ReVia (New drug) 22(2) 43-7 |
|
herpes labialis
|
| penciclovir - Vectavir (New drug) 20(3) 77-9 |
|
herpes simplex
|
| genital herpes |
| abnormal laboratory results 30(1) 8-13 |
| acyclovir (letter) 17(2) 28-9 |
| dental notes 30(1) 13 |
|
Herpes virus infections
|
| ocular - management 17(3) 66-8 |
|
herpes zoster
|
| famciclovir - Famvir (New drug) 18(3) 58-9 |
| vaccine, Zostavax (New drug) 31(1) 24-7 |
| valaciclovir - acyclovir ester - Valtrex (New drug) 19(4) 108-11 |
| varicella vaccination (letter) 30(5) 116 |
|
Hexalen
|
| see hexamethylmelamine 17(2) 30-2 |
|
hexamethylmelamine
|
| ovarian cancer - Hexalen (New drug) 17(2) 30-2 |
|
HighWire Press
|
| online information services and general practice 27(1) 16-8 |
|
hirsutism
|
| eflornithine hydrochloride - Vaniqa - facial hair (New drug) 29(3) 84-7 |
| fertility testing - abnormal laboratory results 25(2) 38-40 |
| polycystic ovary syndrome 27(5) 129-31 |
|
histamine H1 blockers
|
| azelastine - allergic rhinitis - AZEP (New drug) 25(2) 44-7 |
| distribution in human milk 20(2) 35-40 |
| ketotifen - seasonal allergic conjunctivitis - Zaditen (New drug) 28(1) 19-23 |
| levocabastine - Livostin (New drug) 19(3) 81-3 |
| olopatadine - allergic seasonal conjunctivitis - Patanol (New drug) 25(6) 147-51 |
| urticaria management 24(5) 124-6 |
|
histamine H2 blockers
|
| acid peptic disease 18(4) 97-9 |
| adverse effects - 23(6) 123 |
| peptic ulcer and gastro-oesophageal reflux 23(3) 57-9 |
|
HIV/AIDS
|
| abacavir - Ziagen (New drug) 22(5) 125-7 |
| abnormal laboratory results 30(1) 8-13 |
| amprenavir - Agenerase (New drug) 25(2) 44-7 |
| antiretroviral therapy 28(6) 146-9; 26(3) 59-61 |
| atazanavir - Reyataz (New drug) 27(6) 159-65 |
| atovaquone - Pneumocystis - Wellvone (New drug) 18(3) 58-9 |
| cidofovir - cytomegalovirus retinitis - Vistide (New drug) 22(2) 43-7 |
| combination therapy 21(2) 44-6 |
| letter 21(4) 87-91 |
| darunavir - Prezista (New drug) 30(3) 79-82 |
| daunorubicin, liposomal - Kaposis sarcoma - DaunoXome (New drug) 21(3) 80-3 |
| delarvidine mesylate - Rescriptor (New drug) 21(2) 49-55 |
| dental notes 28(6) 149 |
| efavirenz - Stocrin (New drug) 22(6) 147-51 |
| emtricitibine - Emtriva (New drug) 28(2) 49-51 |
| enfuvirtide - HIV infection - Fuzeon (New drug) 27(6) 159-65 |
| fosamprenavir - Telzir (New drug) 28(1) 19-23 |
| indinavir - Crixivan (New drug) 19(4) 108-11 |
| lamivudine - 3TC (New drug) 19(4) 108-11 |
| lopinavir - ritonavir combination - Kaletra (New drug) 24(6) 155-8 |
| needle-stick injuries 24(4) 98-100 |
| nelfinavir - Viracept (New drug) 21(2) 49-55 |
| nevirapine - Viramune (New drug) 20(4) 101-3 |
| patient support organisations 26(3) 61 |
| ritonavir - Norvir (New drug) 20(1) 22-3 |
| saquinavir - Invirase (New drug) 19(4) 108-11 |
| stavudine - Zerit (New drug) 19(3) 81-3 |
| stavudine - Zerit (New formulation) 22(4) 95-8 |
| tenofovir disoxopril fumarate - Viread (New drug) 25(6) 147-51 |
| tipranavir - Aptivus (New drug) 30(4) 107-11 |
| vaccination and travel 23(5) 107-9 |
| valganciclovir - cytomegalovirus retinitis - Valcyte (New drug) 25(6) 147-51 |
|
Holoxan
|
| see ifosfamide 17(1) 6-8 |
|
home care services
|
| domiciliary oxygen therapy 19(3) 69-71 |
| hospital in the home 20(4) 88-9 |
| 'Hospital in the home' (book review) 26(4) 93 |
|
hormone replacement therapy
|
| (editorial) 23(5) 90-2; 17(1) 2-4 |
| breast cancer risks (letter) 17(1) 4-5 |
| levonorgestrel - Mirena (New delivery system) 24(2) 43-7 |
| oestradiol medroxyprogesterone combination - Divina (New drug) 18(3) 58-9 |
| regimens 17(1) 13-6 |
| oestrogens and progestogens after hysterectomy (letter) 17(4) 79-81 |
| risk of thromboembolism 25(3) 57-9 |
| risks and benefits 26(1) 8-10 |
| scientific evidence and advice to patients 25(3) 60-2 |
| letters 25(5) 104-7 |
| sport drug testing (letter) 18(3) 56-7 |
|
hospital in the home
|
| book review 26(4) 93 |
|
hospitals
|
| discharge medication - information and prescriptions (editorial) 29(3) 58-9 |
| letters 29(5) 121 |
| electronic prescribing (editorial) 24(1) 2-3 |
| letters 24(4) 80-2 |
| needle-stick injuries 24(4) 98-100 |
| nutrition and surgical outcomes 26(6) 136-40 |
| prescribing improvements 24(2) 29-31; 24(2) 32 |
| letter 24(4) 80-2 |
|
human chorionic gonadotrophin
|
| biochemical tests for abnormalities in pregnancy 29(2) 48-52 |
|
human papillomavirus vaccine
|
| Cervarix (New drug) 30(5) 133-5 |
| Gardasil (New drug) 29(5) 138-43 |
|
human tumour necrosis factor blockers
|
| etanercept - rheumatoid arthritis - Enbrel (New drug) 25(1) 20-3 |
|
Humira
|
| see adalimumab 27(4) 101-5 |
|
Hycamtin
|
| see topotecan 20(4) 101-3 |
|
hydrochlorothiazide
|
| with enalapril maleate (New combination) 24(1) 20-3 |
| with eprosartan - Teveten Plus (New combination) 25(6) 147-51 |
| with fosinopril sodium - Monoplus (New combination) 23(6) 137-9 |
| with irbesartan - Avapro HCT (New combination) 23(6) 137-9 |
| with quinapril - Accuretic (New combination) 25(5) 120-3 |
|
hydrocolloids
|
| as wound dressings 19(1) 11-3 |
|
hydrocorticosone
|
| in autoimmune disease 22(1) 9-11 |
| clinical pharmacology in asthma 19(2) 44-7 |
| doctors bag supplies for asthma (letter) 20(2) 31-2 |
|
hydrogels
|
| as wound dressings 19(1) 11-3 |
|
hydrogen peroxide in wound debridement
|
| letter 19(3) 59-62 |
|
hydromorphone
|
| opioid analgesic - Dilaudid (New drug) 23(4) 84-7 |
| Palladone XL (New formulation) 28(3) 75-9 |
|
hydrotherapy
|
| in osteoarthritis 18(1) 2-4 |
|
hydroxychloroquine
|
| in adult rheumatoid arthritis 26(2) 36-40 |
|
hyoscine
|
| adverse reaction reporting 28(6) 140-2 |
|
hyperactivity disorder in children
|
| letters 19(3) 59-62; 19(2) 36-8; 19(1) 3-6 |
| methylphenidate (PBAC question) 24(5) 119 |
| psychotropic drugs for children in general practice 28(5) 116-8 |
| stimulant treatment 18(3) 60-3 |
|
hyperaldosteronism
|
| abnormal laboratory results 30(6) 147-9 |
|
hypercalcaemia
|
| cinacalcet - Sensipar (New drug) 28(3) 75-9 |
| tumour-induced - clodronate - Bonefos (New drug) 20(2) 45-51 |
| tumour-induced - zoledronic acid - Zometa (New drug) 25(1) 20-3 |
|
hypercholesterolaemia
|
| atorvastatin - Lipitor (New drug) 21(2) 49-55 |
| cerivastatin - Lipobay (New drug) 22(4) 95-8 |
| ezetimibe - Ezetrol (New drug) 26(6) 146-51 |
| in dyslipidaemia (RADAR comment) 27(5) 128 |
| fenofibrate - Lipidil (New drug) 27(4) 101-5 |
| fluvastatin - Lescol (New drug) 19(1) 24-7 |
| HDL cholesterol - Sheffield tables 21(4) 98-9 |
| HMG CoA reductase inhibitors - clinical trials 22(5) 114-7 |
| letter 22(6) 131-2 |
| HMG CoA reductase inhibitors and myocardial infarction (editorial) 21(4) 86-7 |
| rosuvastatin - Crestor (New drug) 29(6) 167-71 |
|
hypericum
|
| complementary medicines safety (editorial) 25(3) 50-1 |
| St John's wort as antidepressant 22(5) 112-3 |
| letter 23(1) 5 |
|
hyperkinesis in children
|
| stimulant treatment 18(3) 60-3 |
| letters 19(3) 59-62; 19(2) 36-8; 19(1) 3-6 |
|
hyperlipidaemia (see also antilipidaemic drugs)
|
| atorvastatin - hypercholesterolaemia - Lipitor (New drug) 21(2) 49-55 |
| ezetimibe in dyslipidaemia (RADAR comment) 27(5) 128 |
| fenofibrate - Lipidil (New drug) 27(4) 101-5 |
| fish oil preparations in hypertriglyceridaemia (PBAC question) 19(2) 51 |
| fluvastatin - hypercholesterolaemia - Lescol (New drug) 19(1) 24-7 |
| HDL cholesterol - laboratory results 17(4) 99-102 |
| in type 2 diabetes 22(3) 67-9; 20(3) 65-7 |
|
hypermagnesaemia
|
| abnormal laboratory results 30(4) 102-5 |
|
hyperparathyroidism
|
| cinacalcet - Sensipar (New drug) 28(3) 75-9 |
|
hyperphosphataemia
|
| lanthanum carbonate hydrate - chronic renal failure - Fosrenol (New drug) 29(2) 53-5 |
| sevelamer - chronic renal disease -Renagel (New drug) 28(6) 156-8 |
|
hyperprolactinaemia
|
| cabergoline - Dostinex (New drug) 19(1) 24-7 |
| quinagolide - Norprolac (New drug) 28(6) 156-8 |
|
hypersensitivity
|
| immunotherapy 26(4) 91-3 |
| testing - abnormal laboratory results 25(4) 91-3 |
|
hypertension (see also antihypertensives)
|
| ACE inhibitors vs diuretics 27(4) 98-101 |
| ambulatory blood pressure monitoring 20(1) 18-20 |
| beta blockers 30(1) 5-7 |
| letter 30(3) 59-63 |
| combination antihypertensives 24(5) 126 |
| consensus conference (editorial) 17(2) 26-7 |
| in diabetes 25(1) 8-10 |
| letter 25(3) 51-3 |
| in elderly 20(1) 20-4 |
| HOT study - optimal treatment 26(3) 53-5 |
| letters 26(5) 99-102 |
| management of uncomplicated hypertension 28(2) 34-7 |
| letter 28(5) 113-5 |
| paracetamol and blood pressure (letter) 30(3) 59-63 |
| in type 2 diabetes 20(3) 65-7 |
|
hypertension, ocular
|
| travoprost - Travatan (New drug) 25(3) 74-5 |
|
hypertension, pulmonary
|
| epoprostenol - Flolan (New drug) 25(6) 147-51 |
| treprostinil - Remodulin (New drug) 27(6) 159-65 |
|
hyperthyroidism
|
| management 17(3) 70-2 |
| thyroxine administration and pharmacokinetics 27(3) 75-6 |
|
hyperuricaemia
|
| in chemotherapy - rasburicase - Fasturtec (New drug) 26(3) 68-71 |
|
hyperventilation
|
| cognitive behaviour therapy 24(2) 33-7 |
| letters 24(2) 27-8 |
|
hypnotics
|
| management of insomnia 26(4) 78-81 |
| letter 26(6) 124-5 |
| temazepam capsules and injecting drug users 27(3) 58-9 |
| letter 27(5) 109-13 |
|
Hypnovel
|
| see midazolam 17(2) 30-2 |
|
hypodermic syringes
|
| rational use of injections 22(6) 145-7 |
|
hypoglycaemia
|
| glucose 50% vs glucagon in doctors bag supplies (PBAC question) 20(2) 33-4 |
|
hypoglycaemic drugs
|
| drug interactions 24(4) 83-5 |
| exenatide - type 2 diabetes - Byetta (New drug) 30(6) 163-7 |
| and insulin dosages 25(2) 29-31 |
| letter 25(5) 104-7 |
| insulin therapy in diabetes 27(4) 93-6 |
| metformin in pregnancy and lactation 30(3) 68-9 |
| thiazolidinedione pharmacology 27(3) 67-70; 27(3) 70-4 |
|
hypokalaemia
|
| intravenous potassium chloride fatalities 28(1) 14-6 |
| letters 28(4) 84-7 |
|
hypomagnesaemia
|
| abnormal laboratory results 30(4) 102-5 |
| letter 30(6) 140-41 |
|
hyponatraemia
|
| drug-induced 26(5) 114-7 |
| letters 27(3) 55-7; 27(2) 28-33 |
| omeprazole 28(2) 48-9 |
| tramadol-induced 27(4) 97 |
| letter 28(2) 29-33 |
|
hypotension, postural
|
| adverse effect of prazosin 18(1) 21-2 |
|
hypothyroidism
|
| management 17(3) 70-2 |
| subclinical - management 22(6) 132-4 |
| thyroxine administration and pharmacokinetics 27(3) 75-6 |
| shelf-life of thyroxine (letter) 28(1) 5-7 |
| and refrigeration (letter) 29(2) 32-5 |
|
hypovolaemia
|
| pentastarch - Voluven (New drug) 30(4) 107-11 |
|
hypoxaemia
|
| home oxygen therapy 19(3) 69-71 |
| oximetry 26(6) 132-5 |
|
hysterectomy
|
| hormone replacement therapy (letter) 17(4) 79-81 |
|
Hytrin
|
| see terazosin hydrochloride 18(1) 7-9 |
Home
